Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jenna L Voellinger"'
Autor:
Jenna L. Voellinger, Edward J. Kelly
Publikováno v:
ADMET and DMPK, Vol 4, Iss 2, Pp 62-83 (2016)
Primary human hepatocytes are commonly used to evaluate liver drug metabolism and toxicity. Pluripotent stem cell derived hepatocytes (SCDHs) have the potential to overcome access and function-related limitations associated with primary hepatocytes.
Externí odkaz:
https://doaj.org/article/6815d6df102545f6b2ab8c90ef0be7c4
Autor:
Stefan Faderl, Dale L. Bixby, Megan M. O'Meara, Phoenix A. Ho, Moshe Yair Levy, Harry P. Erba, Anjali S. Advani, Anthony S. Stein, Jenna L Voellinger, Farhad Ravandi, Roland B. Walter, Jeffrey E. Lancet, Amir T. Fathi, Daniel J. DeAngelo, Eytan M. Stein, Tibor Kovacsovics, Anand Jillella
Treatment of acute myeloid leukemia (AML) among the elderly is challenging because of intolerance of intensive therapy and therapy-resistant biology. Hypomethylating agents (HMAs) are commonly used, with suboptimal outcomes. Vadastuximab talirine is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c84751e56edf80512a87018fa74e9a43
https://europepmc.org/articles/PMC6265631/
https://europepmc.org/articles/PMC6265631/
Autor:
Rachel M. Shaffer, Terrance J. Kavanagh, Charles L. White, Kirk P. Van Ness, David L. Eaton, Edward J. Kelly, Jenna L. Voellinger, Brian D. Chapron, Shih-Yu Chang, Thomas Neumann
Publikováno v:
Toxicology in vitro : an international journal published in association with BIBRA. 40
The liver is the main site for drug and xenobiotics metabolism, including inactivation or bioactivation. In order to improve the predictability of drug safety and efficacy in clinical development, and to facilitate the evaluation of the potential hum
Autor:
Danny D. Shen, Kimberly A. Muczynski, Brian D. Chapron, Dale W. Hailey, Yoshiyuki Yamaura, Jenna L. Voellinger, Elijah J. Weber, Jonathan Himmelfarb, Edward J. Kelly, Thomas Neumann, Kevin A. Lidberg, Alenka Chapron, Zhican Wang, Kenneth E. Thummel, Catherine K. Yeung
The kidney proximal tubule is the primary site in the nephron for excretion of waste products through a combination of active uptake and secretory processes and is also a primary target of drug-induced nephrotoxicity. Here, we describe the developmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0555ce32289b334c0056b0aa43f37922
https://europepmc.org/articles/PMC4987715/
https://europepmc.org/articles/PMC4987715/
Autor:
Edward J. Kelly, Jenna L. Voellinger
Publikováno v:
New Horizons in Predictive Drug Metabolism and Pharmacokinetics ISBN: 9781849738286
Stem cells have a high self-renewal capability and can give rise to any cell in the body making them a very attractive target for researchers in regenerative medicine, as well as drug discovery and development. Preclinical screening of drug metabolis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c5bfe25d913cc7fde584f2d95e740ac
https://doi.org/10.1039/9781782622376-00177
https://doi.org/10.1039/9781782622376-00177
Publikováno v:
Cancer Research. 77:CT120-CT120
Background CD33 is expressed on myeloblasts in the majority of patients with AML. Vadastuximab talirine (33A) is a potent, highly stable antibody-drug conjugate composed of a humanized CD33-directed antibody conjugated at engineered cysteine residues
Autor:
Justina C. Calamia, Jashvant D. Unadkat, Danny D. Shen, Qingcheng Mao, Edward J. Kelly, Mary F. Hebert, Diana L. Shuster, Bhagwat Prasad, Jenna L. Voellinger, Kenneth E. Thummel, Linda J. Risler
Publikováno v:
Biochemical pharmacology. 92(4)
Glyburide is commonly prescribed for the treatment of gestational diabetes mellitus; however, fetal exposure to glyburide is not well understood and may have short- and long-term consequences for the health of the child. Glyburide can cross the place
Autor:
Farhad Ravandi, William B. Donnellan, Scott E. Smith, Stefan Faderl, Michael B. Maris, Sumithira Vasu, Harry P. Erba, Anthony S. Stein, Eric J. Feldman, Jenna L Voellinger, Brent L. Wood, Anjali S. Advani, Moshe Yair Levy, Amir T. Fathi, Roland B. Walter, Jay Yang
Publikováno v:
Blood. 128:340-340
Background Post-remission therapies for patients with AML such as high-dose cytarabine (HiDAC) and allogeneic stem cell transplant (alloSCT) have led to improved outcomes for younger patients, but disease recurrence remains prevalent with ~40% 5-year
Autor:
Eytan M. Stein, Farhad Ravandi, Amir T. Fathi, Anthony S. Stein, Anand Jillella, Megan M. O'Meara, Anjali S. Advani, Daniel J. DeAngelo, Jeffrey E. Lancet, Jenna L Voellinger, Harry P. Erba, Dale L. Bixby, Stefan Faderl, Tibor Kovacsovics, Moshe Yair Levy, Phoenix A. Ho, Roland B. Walter
Publikováno v:
Blood. 128:590-590
Background CD33is expressed in approximately 90% of AML cases, representing a promising target despite age, prior therapies, or mutational heterogeneity. Vadastuximab talirine (33A) is a CD33-directed antibody conjugated to 2 molecules of a pyrrolobe
Autor:
Farhad Ravandi, Moshe Yair Levy, Stefan Faderl, Sumithira Vasu, Eric J. Feldman, Brent L. Wood, Anjali S. Advani, Roland B. Walter, Jenna L Voellinger, Jay Yang, Scott E. Smith, Harry P. Erba, Michael B. Maris, William B. Donnellan, Anthony S. Stein, Amir T. Fathi
Publikováno v:
Blood. 128:211-211
Background For patients who are less than 65 years with newly diagnosed AML, standard induction treatment is continuous infusion cytarabine for 7 days and an anthracycline for 3 days (7+3). Although a high percentage of patients achieve an initial CR